<DOC>
	<DOC>NCT00525096</DOC>
	<brief_summary>To discover if the adding of a coxib increases the efficacy of the Aromasine.</brief_summary>
	<brief_title>Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Femal patient aged &gt; 18 years Histologically proven breast cancer Menopausal patient according to the following definition: amenorrhoea &gt; 1 year or menopause affirmed by a rate of oestradiol or hypophyseal gonadotrophin surgical ovariectomy treatment by LHRH analog ovarian suppression by radiotherapy amenorrhoea induced by chemotherapy &gt; 1 year Oestradiol and/or progesterone positive receptors Presence of one or several metastatic lesion: mesurable lesion bone metastase were detected by bone scintigraphy Patient who can have received: Adjuvant chemotherapy and/or hormonotherapy (Tamoxifen) Metastatic Treatment by chemotherapy PS &lt; 2 Adequate biological values Patient who has clearly given her consent by signing on informed consent form prior to participation Patient previously treated with hormonotherapy in metastatic phase Antecedent of treatment with aromatase inhibitors local relapse (with the exception of cutaneous thoracic nodes) Patient with only one metastatic lesion like: pleurisy , ascites, lung Lymphangitis carcinomatosa</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>